- Home
- XFOR vs AUDC Comparison
XFOR vs AUDC Comparison
Compare XFOR & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XFOR | AUDC |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 267.0M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | XFOR | AUDC |
|---|---|---|
| Price | $3.98 | $8.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.50 | $11.67 |
| AVG Volume (30 Days) | ★ 879.6K | 83.3K |
| Earning Date | 11-05-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 4.58% |
| EPS Growth | N/A | ★ 15.76 |
| EPS | N/A | ★ 0.46 |
| Revenue | $33,979,000.00 | ★ $244,553,000.00 |
| Revenue This Year | $1,276.65 | $2.98 |
| Revenue Next Year | N/A | $3.40 |
| P/E Ratio | ★ N/A | $18.78 |
| Revenue Growth | ★ 2925.74 | 0.15 |
| 52 Week Low | $1.35 | $8.01 |
| 52 Week High | $26.83 | $12.72 |
Technical Indicators
Market Signals| Indicator | XFOR | AUDC |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 44.70 |
| Support Level | $3.50 | $8.79 |
| Resistance Level | $4.56 | $8.96 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 47.91 | 14.29 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.